4ogv: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4ogv]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OGV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OGV FirstGlance]. <br> | <table><tr><td colspan='2'>[[4ogv]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OGV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OGV FirstGlance]. <br> | ||
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2U7:[(2S,5R,6R)-4-[(2S)-1-(TERT-BUTYLSULFONYL)BUTAN-2-YL]-6-(3-CHLOROPHENYL)-5-(4-CHLOROPHENYL)-3-OXOMORPHOLIN-2-YL]ACETIC+ACID'>2U7</scene>< | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2U7:[(2S,5R,6R)-4-[(2S)-1-(TERT-BUTYLSULFONYL)BUTAN-2-YL]-6-(3-CHLOROPHENYL)-5-(4-CHLOROPHENYL)-3-OXOMORPHOLIN-2-YL]ACETIC+ACID'>2U7</scene></td></tr> | ||
<tr><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MDM2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MDM2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ogv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ogv OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ogv RCSB], [http://www.ebi.ac.uk/pdbsum/4ogv PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ogv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ogv OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ogv RCSB], [http://www.ebi.ac.uk/pdbsum/4ogv PDBsum]</span></td></tr> | ||
<table> | </table> | ||
== Disease == | == Disease == | ||
[[http://www.uniprot.org/uniprot/MDM2_HUMAN MDM2_HUMAN]] Note=Seems to be amplified in certain tumors (including soft tissue sarcomas, osteosarcomas and gliomas). A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding. | [[http://www.uniprot.org/uniprot/MDM2_HUMAN MDM2_HUMAN]] Note=Seems to be amplified in certain tumors (including soft tissue sarcomas, osteosarcomas and gliomas). A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding. | ||
| Line 24: | Line 24: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | [[Category: Human]] | ||
[[Category: Huang, X | [[Category: Huang, X]] | ||
[[Category: Long, A M | [[Category: Long, A M]] | ||
[[Category: Shaffer, P L | [[Category: Shaffer, P L]] | ||
[[Category: Yakowec, P | [[Category: Yakowec, P]] | ||
[[Category: Ligase-ligase inhibitor complex]] | [[Category: Ligase-ligase inhibitor complex]] | ||
[[Category: P53]] | [[Category: P53]] | ||
[[Category: Protein-protein interaction]] | [[Category: Protein-protein interaction]] | ||